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Abstract
Effective population screening of HIV and prevention of HIV transmission are only part of the global fight against AIDS.
Community-level effects, for example those aimed at thwarting future transmission, are potential outcomes of treatment
and may be important in stemming the epidemic. However, current clinical trial designs are incapable of detecting a
reduction in future transmission due to treatment. We took advantage of the fact that HIV is an evolving pathogen whose
transmission network can be reconstructed using genetic sequence information to address this shortcoming. Here, we use
an HIV transmission network inferred from recently infected men who have sex with men (MSM) in San Diego, California. We
developed and tested a network-based statistic for measuring treatment effects using simulated clinical trials on our
inferred transmission network. We explored the statistical power of this network-based statistic against conventional
efficacy measures and find that when future transmission is reduced, the potential for increased statistical power can be
realized. Furthermore, our simulations demonstrate that the network statistic is able to detect community-level effects (e.g.,
reduction in onward transmission) of HIV treatment in a clinical trial setting. This study demonstrates the potential utility of
a network-based statistical metric when investigating HIV treatment options as a method to reduce onward transmission in
a clinical trial setting.
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Introduction
Randomized trials of preventive measures against HIV, such as
male circumcision [1–3], vaginal microbicide gel [4], pre-exposure
prophylaxis (PrEP) [5,6], and vaccination [7], have demonstrated
modest but potentially important benefits. In studies to date, such
interventions have had estimated efficacy levels of 30–50% in
preventing individual infections. What remains to be quantified,
however, is the potential such interventions have for larger
community-level effects (i.e. reduced infectiousness leading to
lower disease burden). It is unknown whether any current
intervention strategy could meet the public health goal of bringing
an epidemic under control.
Prevention and treatment efforts [e.g. imperfect vaccination,
PrEP followed by antiretroviral treatment (ART), or test-and-
treat] could reduce onward transmission by decreasing the viral
load of infected individuals [8]. Even interventions that were
ineffective or not intended to prevent infections (e.g. test-and-treat
[9]) may prove useful in lowering HIV’s capacity for future
infection by reducing viral load [10,11]; such effects would likely
be of great benefit to the susceptible population as a whole. It is
noteworthy that single or two-drug ART combinations are
sufficient for substantial reductions in maternal-child transmission,
even though such therapies are not adequate for complete
suppression of HIV [12]. Current clinical trials are not designed
to detect a decrease in onward transmission as an effect of an
intervention at the community level. Although group-level
randomized trials have been undertaken [13], such studies are
logistically complex and not always practical. This manuscript
addresses the question of how to use putative transmission network
information inferred from individual-level randomized studies to
learn about the community-level impact of prevention strategies.
HIV prevention trials face a combination of formidable
obstacles: relatively low efficacy (around 30%) and a low incidence
of HIV infections (#1% per year) in most populations. This
combination often results in relatively low statistical power (,80%)
to detect efficacious intervention, even for very large numbers of
trial participants (,10000 per arm). The recent CAPRISA
microbicide trial in South Africa is an exception, which was able
to conduct the study in a population with an unusually high
incidence of HIV (around 10%) [4].
Statistical tests used to detect the efficacy of prevention and
intervention treatments take into account the time of infection of
study subjects but not the evolutionary transmission history of the
virus. HIV is a measurably evolving pathogen, and changes in its
genetic sequence over time have been successfully used to
reconstruct recent individual-to-individual transmission histories
[14–20]. These transmission histories are traditionally represented
as phylogenetic trees, but they can also be depicted as (incomplete)
transmission networks. These networks are comprised of nodes,
representing HIV-infected individuals, which are connected by
edges if the genetic similarity or phylogenetic relatedness of the
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transmission network can be described using a variety of statistics,
one of which is degree: the number of edges connecting to a given
node.
Here we propose a statistical metric that accounts for the
evolutionary relatedness of the virus and address two questions: (i)
can transmission networks provide a basis for developing more
powerful statistical metrics to measure prevention effeciveness, and
(ii) can these transmission networks be used to detect decreases in
viral transmission from study participants to others in their sexual
network? Through simulations on a transmission network inferred
from men who have sex with men (MSM), we demonstrate how
our network metric can be more powerful than current methods in
a clinical trial setting. In principle, clinical trials using this network
statistic should be able to detect a decrease in secondary
transmission, even if treatment fails to prevent primary infection.
Methods
Ethics statement
Written informed consent was obtained from all patients, and
the human experimentation guidelines of the US Department of
Health and Human Services were followed in conducting this
research. The US Department of Health and Human Services has
also issued a Confidentiality Certificate to all studies of the
University of California, San Diego involving acute and early HIV
infection and recruitment of sexual partners. Collection of these
data was approved by the University of California, San Diego
Institutional Review Board. The sequence data were anonymized.
Construction of the transmission network
Genetic distances among HIV sequences were calculated using
pol fragments sampled from N=502 HIV-infected MSM from the
San Diego, California area between 1996 and 2009. All samples
were obtained during acute and early stages of infection. To
construct the transmission network, a connection (i.e. edge) was
placed between any two individuals (i.e. nodes) whose viral
sequences were ,1% distant under a codon-model based
synonymous distance estimated using maximum likelihood. This
1% cut-off was chosen based on previous studies [22] and by
inspecting the distribution of pairwise distances between putatively
unrelated pol sequences (subtype B) available from the Los Alamos
HIV database (http://www.hiv.lanl.gov/). Importantly, an edge
between two nodes does not indicate direct transmission between
two individuals, only a close association. Therefore, nodes may be
connected through an edge even though the individuals repre-
sented may never have had physical contact. Also, the edges in our
network are undirected.
Clinical trial simulations
We assumed that our simulated clinical trials contained 10,000
participants (5000 in each arm) who become infected at a given
rate (incidence rate =0.02 infections per length of trial [2,6,7])
(Figure 1a). In the absence of an effective intervention, we expect
an average of 100 infected individuals in each arm. To simulate a
clinical trial of a given duration, we first sampled the number of
infected individuals in the treatment (T) and placebo (P) arms
using the binomial distribution, where the incidence in the
treatment arm was reduced by the assumed treatment efficacy.
Next, T random nodes in the network were assigned treatment
arm, P – the placebo arm, and the remainder (N minus T minus P)
– to infected community members who were not participating in
the trial (Figure 1b). A proportion of edges connecting to treatment
nodes were removed to approximate (i) the reduction of the
number of opportunities for future transmission resulting from the
delay in initial infection due to treatment and/or (ii) the reduction
in the probability of future transmission of the virus due to
efficacious treatment (Figure 1c).
Clinical trials were simulated for: (i) treatments with varying
efficacy (i.e. prevention/delay of infection: 0–40%), corresponding
to the reduction of the number of nodes in the treatment arm, and
(ii) varying efficacy of preventing future infection (i.e. reduced
transmissibility/delay of initial infection: 0–100%), corresponding
to the reduction in the number of edges connecting to the nodes
on treatment. For each scenario, 10,000 clinical trials were
simulated, and at the end of each trial, the statistical power of two
metrics used to gauge the efficacy of treatment was compared.
The first metric (referred to as the Number Infected Statistic)
used the number of infected participants in each arm. The
difference between the number of infected individuals in the
treatment and placebo arms was calculated. To assess the
significance of this difference, we calculated the null distribution
of the Number Infected Statistic by performing permutation tests
in which the status (treatment versus placebo) of each infected trial
participant, represented by a node, was assigned randomly, as if
treatment were ineffective, and the difference between the number
Figure 1. Procedure for simulation of clinical trial on mock
network. The clinical trial depicted here has a treatment efficacy of
25% (3 participants on treatment, shown in white, versus 4 on placebo,
shown in gray) with an edge removal rate of 40% (2 out of 5 edges
connected to infected treatment cases). (a) First, the network is
constructed using a synonymous sequence divergence cut-off. (b) Next,
trial status is assigned: treatment in white, placebo in gray, and
community members in black. Treatment nodes are infected at a
reduced rate reflecting treatment efficacy. (c) Edges are then removed
from treatment nodes at a given rate to represent the reduction in
transmission due to delay in infection and reduction in forward
transmission. The metrics are then calculated. The Network Statistic
metric is 6 for treatment and 9 for placebo; the Number Infected
Statistic is 3 for treatment and 4 for placebo. (d) Finally, a permutation
test to determine significance is performed on the modified network by
randomizing the assignment of treatment and placebo. Community
nodes remain unaltered by the permutation.
doi:10.1371/journal.pone.0027775.g001
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Treatment status was permuted 10,000 times to construct the
null distribution with a=0.05 (Figure 1d). Note that this
procedure is a permutation-based contingency table test, whereas
the null model estimated the (unknown) incidence by the observed
incidence for the entire trial.
The second metric (referred to as the Network Statistic) makes
use of the degree of nodes (the number of edges connected to a
given node). Each node (representing an infected trial participant)
was given a score: the degree of that node plus 1, to account for the
fact that the study participant was infected. Therefore, in the
absence of any network connections, the Network Statistic is
identical to the Number Infected Statistic. The difference between
the cumulative scores of infected individuals in the treatment and
placebo arms was calculated. To assess the significance of this
difference, we calculated a null distribution by performing a
permutation test in the same manner as described above
(Figure 1d). The procedure was implemented in Python. The
code and the anonymized network structure for the San Diego
cohort can be downloaded from http://www.hyphy.org/pubs/
NetworkStats/.
Results
The inferred San Diego network was relatively sparse,
containing only 345 edges on 502 nodes when using a 1%
synonymous divergence cut-off. Slightly less than half of the nodes
(47%) had a degree of one or greater (i.e. at least one edge
connected to the node) (Figure 2). The mean degree for all nodes
was 1.37, and the maximum degree for a node in the network was
18.
We simulated clinical trials on the HIV transmission network,
inferred from the San Diego MSM population, in which the
efficacy of treatment varied between 0 and 40%. Using these
simulated clinical trials, the statistical power of the Number
Infected and the Network Statistics was assessed. We also allowed
for the possibility that the intervention both prevented infection
and reduced the potential for onward transmission of the virus
over a varying range of efficacies, as might arise from the use of
PrEP and ART.
At every level of intervention efficacy examined, the Network
Statistic demonstrated the potential for increased statistical power
compared with the Number Infected Statistic (Figure 3). The
actual increase in statistical power depended on the proportion of
edges removed from each node undergoing treatment due to
either a (i) delay in initial infection or (ii) reduction in the
probability of future transmission. We note, however, that power
gains relative to the Number Infected Statistic were observed only
when the number of edges removed exceeded the efficacy of the
intervention (i.e. when the number of subsequent infections is
reduced to a greater extent than would arise solely from having
prevented the infection of the study participant). A plausible
example of this scenario would be through a reduction in viral load
through ART. The magnitudes of the potential gains in statistical
Figure 2. Histogram depicting the distribution of degree across nodes in the San Diego network.
doi:10.1371/journal.pone.0027775.g002
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treatment efficacy was low, since the Number Infected Statistic
becomes well powered ($80%) when treatment efficacy reached
35%. Importantly, even though our inferred network was
relatively sparse and did not represent the complete transmission
network, we still observed the potential for substantial gains in
statistical power. Importantly, the Network Statistic and its
permutation test preserved the Type-I error rate – the possibility
of incorrectly rejecting the null (see Figure 3: 0% efficacy, 0% edge
removal rate).
Next, we explored the impact of the number of community
nodes, representing infected individuals who were not study
participants, on statistical power. We simulated clinical trials with
limited community sampling (e.g. 0, 100, and 200 community
nodes). In an actual clinical trial, these sequences would be
obtained from individuals who became infected concurrently with
the clinical trial in the same geographical region. The reduction in
the number of community nodes resulted in a lower statistical
power than did trials simulated using the more densely sampled
network (Figure 4). Similar to the above simulations, this difference
was more pronounced at lower levels of efficacy; however, the
decrease in statistical power associated with smaller numbers of
community nodes was not evident at low levels of edge removal.
This relative unimportance of community nodes at low levels of
Figure 3. Statistical power of the Network Statistic on simulated clinical trials as function of the edge removal rate on the San
Diego network. The Network Statistic values are blue dots. The power of the Number Infected Statistic for a given efficacy is a solid red line.
doi:10.1371/journal.pone.0027775.g003
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since most nodes did not share edges with any other nodes,
community or otherwise.
Finally, we explored the utility of our Network Statistic on two
types of simulated transmission networks: scale-free and random.
These simulated networks were constructed to have a similar
number of edges as the inferred San Diego network. The statistical
power of the Network Statistic was greater on these simulated
networks than on the San Diego network (Figure 5). However,
when comparing scale-free and random transmission networks,
the Network Statistic’s power was not consistently better in one
versus the other.
Discussion
These results illustrate potential gains from using network
statistics in the analyses of HIV prevention studies. The value is
twofold: (i) potential increases in power, particularly if the
intervention might have an impact on secondary transmissions
from study participants, and (ii) in certain cases, the ability to
detect effects that go beyond the study participants themselves and
involve the broader community. To assess the actual gains in
power using the Network Statistic will require application to PrEP,
vaccination, or other prevention studies. Nevertheless, the
simulations performed here demonstrate the potential of a simple
network-based statistic that accounts for only first-order network
interactions; more complicated network statistics (e.g. connectivity)
may be even more valuable.
Although accounting for modifications to the network can
increase the probability of detecting an effective intervention, one
would not expect to achieve the maximum power gains attained
here. In practice, unless direction of infection can be ascertained,
one would never observe a 100% reduction in edges connected to
nodes representing infected study subjects if the network is fully
sampled. This is because a source partner node will share at least
one edge with the infected recipient (an individual in the treatment
arm). Overall statistical power is also likely decreased because
many transmission events between study participants and other
community members are likely to be missed due to under-
sampling and therefore not included in the network. Nonetheless,
the permutation tests of the Network Statistic are valid regardless
of the amount of genetic information available for recent HIV
infections in a community. Additional information would increase
the statistical power of the Network Statistic.
An important feature of our Network Statistic, as currently
implemented, is its inability to fully distinguish between treatment
effects due to infection prevention and those due to transmission
prevention. Some insight regarding the importance of both effects
can be obtain by comparing the relative magnitudes of the
standardized Network Statistic and Number Infected Statistic;
standardization could be achieved by obtaining a bootstrap
estimate of variance for both statistics. When the Network
Statistic, but not the Number Infected Statistic, shows a significant
treatment difference, the transmission effect may be of greater
importance. In such settings, however, it may still be necessary to
combine across effects to achieve a statistically significant result. In
any case, a significant result using the Network Statistic would
indicate a benefit due to treatment whose exact nature would
require further investigation. There are also important settings
(e.g. clinical trials investigating test-and-treat interventions, in
which all participants are already HIV-positive), where the
outcome of interest is exclusively the network-level effect. In such
settings, interpretation of the Network Statistic as a measure of the
decrease in transmission due to treatment is straightforward.
There are many ways improve the estimation of a transmission
network and the associated statistic. First, directionality of edges in
the network might be available if estimated dates of infection were
observed during the trial or inferred using the results of clinical
tests [23] and/or estimates of viral nucleotide diversity [17,24]. In
addition, we could modify the Network Statistic to weight edges by
the inverse of the genetic distance between nodes, or some other
factor related to the probability of the cluster representing a
transmission event. Furthermore, it would be possible to account
for the temporal nature of network construction in an actual
clinical trial. For the test statistic based on study participants alone,
we could use a standard log-rank test. For the Network Statistic,
we could calculate, for each person, a value at every observed
Figure 4. Statistical power of the Network Statistic as a
function of the edge removal rate and the number of
community nodes. Treatment efficacies of 10%, 20%, and 30% are
shown. ‘All community nodes’ corresponds with the power of the
Network Statistic in Figure 3.
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process for each person that could take on any integer value. From
these values, we could calculate a network-based test statistic. For
example, for both randomized groups, we could sum the degree
over subjects of this process at each event time and then sum the
difference between groups over the event times. Calculation of the
null distribution of this test statistic could be undertaken using
permutation; further work needs to be done to determine the most
powerful tests against different specific alternative hypotheses.
Finally, agent-based modeling simulations may prove useful in
understanding how delay of infection and prevention of transmis-
sion relate to the power of the Network Statistic. This type of study
would allow for a more practical interpretation of the edge
removal rate used in our study. In addition, such simulations will
help determine the most appropriate cases for the implementation
of our novel Network Statistic.
We note that our methods could apply to any pathogen for
which a transmission network can be reconstructed using genetic
sequence information (e.g. hepatitis C virus and influenza A virus)
and any type of prevention study. Perhaps most interesting would
be studies such as PrEP, microbicide, barrier methods, or
vaccination where the intervention may impact future transmis-
Figure 5. Statistical power of the Network Statistic on simulated clinical trials on simulated networks. Scale-free networks are shown in
blue, random networks in green, and the San Diego network in gray. The San Diego network values correspond with the power of the Network
Statistic in Figure 3.
doi:10.1371/journal.pone.0027775.g005
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other mechanism.
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